

November 7, 2022

**Supplementary Documents of Consolidated
Financial Results for the Second Quarter of the Year
Ending March 31, 2023 (FY2022)**



Stock code : 4886 (TSE)

ASKA Pharmaceutical Holdings Co., Ltd.

Statements of Income (Consolidated)

(Millions of yen)	FY2021 Apr - Sep Actual	FY2022 Apr - Sep Actual	Actual +/-	Growth +/-
Net sales	28,477	30,172	1,694	6.0%
Operating profit	2,657	2,879	221	8.3%
Ordinary profit	2,743	2,987	244	8.9%
Profit attributable to owners of parent	- 2,796	2,346	5,143	—

Major factors for the increase in sales and profit

- ✓ The pharmaceutical business showed favorable trends overall. In the field of obstetrics and gynecology, sales of RELUMINA continued to grow significantly from the previous year, while FREWELL showed steady growth, and DroEti, which was launched in June of this year, led the results significantly. In the internal medicine field, sales of RIFXIMA increased by double digits, and THYRADIN also showed steady growth.
- ✓ In the animal health business, sales of feed additives performed well.

Net Sales by Business (Consolidated)

(Millions of yen)	FY2021 Apr - Sep Actual	FY2022 Apr - Sep Actual	Breakdown	Actual +/-	Growth +/-
Pharmaceutical business	25,619	26,851	89.0%	1,231	4.8%
Animal health business	2,791	3,234	10.7%	443	15.9%
Other businesses	66	86	0.3%	19	29.7%
Total	28,477	30,172	100.0%	1,694	6.0%

Sales of Main Products (ASKA Pharmaceutical Co., Ltd.) (Millions of yen)

Area	Category	Products (generic name)	FY2021 Apr - Sep	FY2022 Apr - Sep		FY2022		Reference	Notes
			Actual	Acutual	YOY	Revised Forecast	YOY	Previous Forecast	
Internal Medicine	AG	CANDESARTAN * 1 (candesartan)	6,259	5,477	87.5%	10,697	86.3%	10,840	The NHI drug price has decreased, but sales on a quantity basis have been maintained.
	Brand-name	THYRADIN (levothyroxine)	3,790	3,921	103.5%	7,706	102.8%	7,714	July 2022: 100th anniversary of the brand
	Brand-name	RIFXIMA (rifaximin)	2,464	2,757	111.9%	5,500	113.3%	5,289	
	Brand-name	MERCAZOLE (thiamazole)	751	761	101.4%	1,467	100.6%	1,440	
	Generic	AMLODIPINE (amlodipine)	555	465	83.8%	937	87.3%	963	
Obstetrics and Gynecology	Brand-name	RELUMINA (relugolix)	3,703	4,524	122.2%	9,671	131.9%	9,779	December 2021: Additional indication for endometriosis
	AG	FREWELL (norethisterone/ethinylestradiol)	1,667	1,765	105.9%	3,276	94.6%	3,083	The NHI drug price declined, but sales increased due to market expansion
	Generic	DroEthi (drospirenone/ethinylestradiol)	—	1,279	—	3,023	—	1,944	June 2022: Only ASKA launched
	Brand-name	ANGE (levonorgestrel/ethinylestradiol)	446	420	94.2%	859	100.5%	896	
	Brand-name	LUTEUM (progesterone)	298	569	190.6%	979	148.1%	836	April 2022: Insurance coverage for infertility treatment has been commenced
	Brand-name	MAGSENT * 2 (magnesium sulfate)	467	309	66.2%	644	75.7%	682	Return to the premium for new drug innovation
Urology	Generic	LEUPRORELIN * 3 (leuprorelin)	2,520	2,619	103.9%	5,018	96.8%	4,589	

* 1 Including compounding agents

* 2 Total value of magnesium sulfate preparation

* 3 1.88mg formulation is for gynecological indications only, but combined with 3.75mg formulation

Forecast of Consolidated Financial Results for FY2022

(Millions of yen)	FY2021 Actual	FY2022 Previous Forecast	FY2022 Revised Forecast	YOY Actual +/-	YOY Growth +/-
Net sales	56,607	57,500	60,000	3,392	6.0%
Operating profit	4,795	4,200	5,200	404	8.4%
Ordinary profit	4,880	4,300	5,300	419	8.6%
Profit attributable to owners of parent	4,290	3,300	4,200	- 90	- 2.1%


Analysis of Major factors

- ✓ Net sales are projected to exceed the previous announcement as a result of strong sales of obstetrics and gynecology product groups in the pharmaceutical business and steady sales of feed additives and other products in the animal health business.
- ✓ Both operating profit and ordinary profit are expected to exceed the previous year's levels thanks to the effect of increased sales.
- ✓ Net profit for the year is estimated to be higher than the previous announcement and at the same level as last year, when extraordinary loss and extraordinary profit had an impact on net profit.


Sales Proportion of Brand-name Drugs

■ Brand-name drugs ■ Generic drugs

2Q FY2021




2Q FY2022



The product mix improved due to growth in RELUMINA, RIFXIMA, and THYRADIN, resulting in a 2.1 percentage point increase in the ratio of brand-name drugs to sales

R&D Status

Trend of R&D expenses



Note: Revised from the initial forecast for FY2022

As of November 7, 2022

Development code (Generic name) / Indication	Phase
LF111 (drospirenone) Contraception	Ph III
(Option agreement) Treatment for PMS/PMDD	Ph II (IIT *1)
(Option agreement) Treatment for Cervical Dysplasia	Ph I / II (Korea)
TRM-270 (adhesion barrier) (Gastroenterology and Ob/Gyn)	Ph III *2
L-105 (rifaximin) Hepatic encephalopathy (pediatrics)	Ph II / III
AKP-009 (ludaterone acetate) Benign prostatic hyperplasia	Ph II *3
AKP-022 (Relugolix Combination Tablet) Uterine fibroids	Preparing Development

*1 Investigator-initiated clinical trial

*2 Ph III was initiated in November 2022

*3 Additional Ph I trial at a higher dose ended in April 2022